百亿A股，重大资产重组

Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Shandong Weigao Purui Medical Packaging Co., Ltd. through a share issuance, which is expected to constitute a major asset restructuring and related party transaction [1] Group 1: Transaction Details - The acquisition is expected to be a significant asset restructuring and will involve a suspension of trading for the company's stock starting from October 20, 2025, for no more than 10 trading days [1] - Shandong Weigao Purui was established on September 13, 2018, and its business scope includes the production and sales of Class I and Class II medical devices, as well as the manufacturing of medical packaging materials [1] Group 2: Company Background - Weigao Blood Purification was listed on the Shanghai Stock Exchange on May 19 of this year, focusing on the research, production, and sales of blood purification medical products, including blood dialysis devices and solutions [3] - As of June 30, 2025, Weigao Group is the largest shareholder of Weigao Blood Purification with a 41.75% stake, while Shandong Weigao Group holds 23.9% [3] Group 3: Financial Performance - In the first half of 2025, Weigao Blood Purification achieved a revenue of 1.765 billion yuan, representing a year-on-year increase of 8.52%, and a net profit attributable to shareholders of 220 million yuan, up 10.11% year-on-year [7] - As of October 17, 2025, the stock price of Weigao Blood Purification was 38.61 yuan per share, with a market capitalization of 16.13 billion yuan [7]